Table 1.
Baseline characteristics are shown in the cohort, and in patients with NT-proBNP measured, separated by treatment group
| Variable: | Overall (n = 173) |
Standard group (n = 75) | Aggressive group (n = 78) | ||||
|---|---|---|---|---|---|---|---|
| NT-proBNP ≥ 280* (n = 24) |
NT-proBNP < 280 (n = 51) |
p value | NT-proBNP ≥ 280 (n = 25) |
NT-proBNP < 280 (n = 53) |
p value | ||
| Age (years, mean ± SD) | 59.7 ± 8.7 | 62.7 ± 6.8 | 57.5 ± 9.9 | 0.02 | 62.2 ± 7.4 | 58.7 ± 8.8 | 0.09 |
| Women n (%) | 45 (26.0) | 9 (37.5) | 12 (23.5) | 0.21 | 10 (40) | 9 (17) | 0.03 |
| Type of AF n (%): | 0.09 | 0.06 | |||||
| Persistent | 74 (42.8) | 10 (41.7) | 32 (63) | 11 (44) | 35 (66) | ||
| Paroxysmal | 99 (57.2) | 14 (58.3) | 19 (37.3) | 14 (56) | 18 (34) | ||
| AF duration (months, mean ± SD) | 57.2 ± 71.5 | 42.2 ± 35.6 | 65.5 ± 79.8 | 0.12 | 67.3 ± 99.8 | 51.1 ± 58.7 | 0.52 |
| Systolic Blood Pressure (mmHg, mean ± SD) | 142.6 ± 12.0 | 144.0 ± 16.6 | 141.5 ± 11.0 | 0.50 | 145.5 ± 11.8 | 141.3 ± 10.7 | 0.13 |
| Hypertension n (%) | 130 (75.0) | 20 (83.3) | 36 (70.6) | 0.24 | 18 (72.0) | 42 (79.3) | 0.50 |
| Diabetes n (%) | 22 (12.7) | 2 (8.3) | 7 (13.7) | 0.49 | 3 (12) | 8 (15.1) | 0.71 |
| CHADS2 n (%): | 0.61 | 0.73 | |||||
| 0 | 39 (22.5) | 3 (12.5) | 13 (25.5) | 7 (28) | 11 (20.8) | ||
| 1 | 108 (62.4) | 18 (75.0) | 31 (60.8) | 13 (52) | 33 (62.3) | ||
| 2 | 18 (10.4) | 2 (8.3) | 5 (9.8) | 3 (12) | 7 (13.2) | ||
| > 2 | 8 (4.6) | 1 (4.2) | 2 (3.9) | 2 (8) | 2 (3.8) | ||
| LVEF (%, mean ± SD) | 58.6 ± 8.2 | 58.3 ± 9.4 | 60.1 ± 6.1 | 0.43 | 55.9 ± 12.1 | 59.7 ± 7.6 | 0.19 |
Characteristics are compared between those with NT-proBNP ≥ 280 pg/mL and < 280 pg/mL, within each treatment group. The aggressive cohort had a target blood pressure of < 120/80 mmHg, and the standard cohort had a target of < 140/90 mmHg
AF, atrial fibrillation; SBP, systolic blood pressure; LVEF, left ventricular ejection fraction
*pg/mL